The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 20230 | Causes of acquired resistance in metastatic NSCLC
Biagio Ricciuti, MD, PhD, Dana Farber Cancer Institute, Boston, MA, comments on the causes of acquired resistance to immunotherapy in metastatic non-small cell lung cancer (NSCLC). The incidence of resistance in patients with metastatic NSCLC has highlighted the need for new biomarkers or the optimisation of existing predictive biomarkers in order to inform trial design and clinical practice. Several factors in acquired resistance to immunotherapy have been identified, such as a decrease in the density of CD8+ T cells, a fall in PD-1 and PA-1 engagement, and acquired mutations in genes known to provide primary resistance. Dr Ricciuti shares that these findings are relevant to novel immunotherapies and demonstrate the importance of repeat tumour biopsies. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
